一项评估 Efgartigimod PH20 皮下注射治疗原发性免疫性血小板减少症成人患者的安全性和有效性的 3 期研究 (ADVANCE SC+)
评估 Efgartigimod (ARGX-113) PH20 皮下注射治疗成人原发性免疫性血小板减少症患者的安全性和有效性的 3 期、多中心、开放标签、长期试验
The main aim of the study is to evaluate the safety and efficacy of efgartigimod PH20 SC (subcutaneous) in adult patients with primary immune thrombocytopenia (ITP). Participants who completed the 24-week trial period of the ARGX- 113-2004 trial are given the opportunity to enter into this open-label extension trial and receive efgartigimod PH20 SC.
Participants will be offered the opportunity to continue in this trial if they have completed the first 52-week treatment period unless efgartigimod becomes commercially available for patients with primary ITP or becomes available through another program for patients with primary ITP, whichever comes first. A maximum of three additional 52-week treatment periods will be offered to the participant to continue this trial.
The total trial duration per participant is up to 4 years (52-week treatment period, extendable with three additional 52-week treatment periods) + 8 weeks follow-up period.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国
- Investigator site 860013
-
Bengbu、中国
- Investigator Site 0860008
-
Huizhou、中国
- Investigator site 860055
-
Shenzhen、中国
- Investigator Site 0860015
-
Tianjin、中国
- Investigator Site 0860001
-
Wuhan、中国
- Investigator Site 0860010
-
Wuxi、中国
- Investigator Site 0860002
-
Zhengzhou、中国
- Investigator Site 0860011
-
Zhenjiang、中国
- Investigator site 860058
-
-
-
-
-
Tbilisi、乔治亚州
- Investigator site 9950009
-
Tbilisi、乔治亚州
- Investigator site 9950011
-
Tbilisi、乔治亚州
- Investigator Site 9950007
-
-
-
-
-
Kirov、俄罗斯
- Investigator site 0070040
-
Moscow、俄罗斯
- Investigator Site 0070026
-
Nizhny Novgorod、俄罗斯
- Investigator Site 0070038
-
Novosibirsk、俄罗斯
- Investigator Site 0070037
-
-
-
-
-
Plovdiv、保加利亚
- Investigator Site 3590017
-
-
-
-
-
Johannesburg、南非
- Investigator site 270003
-
Observatory、南非
- Investigator site 270004
-
Pretoria、南非
- Investigator site 270001
-
Randburg、南非
- Investigator site 270002
-
-
-
-
-
Adapazarı、土耳其(türkiye)
- Investigator Site 0900007
-
Ankara、土耳其(türkiye)
- Investigator Site 0900003
-
Ankara、土耳其(türkiye)
- Investigator Site 0900015
-
Ankara、土耳其(türkiye)
- Investigator Site 0900008
-
Izmir、土耳其(türkiye)
- Investigator site 900004
-
Kocaeli、土耳其(türkiye)
- Investigator Site 0900014
-
Mersin、土耳其(türkiye)
- Investigator site 900010
-
Tekirdağ、土耳其(türkiye)、59100
- Investigator site 0900017
-
Trabzon、土耳其(türkiye)
- Investigator site 900019
-
-
-
-
-
Aguascalientes、墨西哥
- Investigator site 520002
-
-
-
-
-
Athens、希腊
- Investigator site 300008
-
Thessaloniki、希腊
- Investigator Site 0300009
-
-
-
-
-
Ferrara、意大利
- Investigator site 390043
-
Milan、意大利
- Investigator Site 0390032
-
Naples、意大利
- Investigator Site 0390044
-
Naples、意大利
- Investigator site 390041
-
-
-
-
-
Sarpsborg、挪威、1714
- Investigator site 0470003
-
-
-
-
-
Christchurch、新西兰
- Investigator site 640005
-
-
-
-
-
Hirakata、日本、5731191
- Investigator site JP0810015
-
Iruma、日本
- Investigator Site 0810017
-
Kanagawa、日本
- Investigator Site 0810053
-
Kitakyushu、日本
- Investigator Site 0810051
-
Shibukawa、日本、377-0280
- Investigator site 0810016
-
Shimotsuke、日本
- Investigator site 810023
-
Tama、日本
- Investigator Site 0810038
-
-
-
-
-
Reñaca、智利
- Investigator site 0560003
-
Santiago、智利
- Investigator site 560002
-
Temuco、智利
- Investigator site 0560004
-
-
-
-
-
Katowice、波兰、40-519
- Investigator site PL0480013
-
Nowy Sącz、波兰
- Investigator Site 0480026
-
Skorzewo、波兰
- Investigator Site 0480037
-
-
-
-
-
Bangkok、泰国
- Investigator Site 0660002
-
Bangkok、泰国
- Investigator Site 0660003
-
Bangkok、泰国
- Investigator site 660005
-
Bangkok Noi、泰国
- Investigator Site 0660001
-
Chiang Mai、泰国、50200
- Investigator site 0660004
-
Khon Kaen、泰国
- Investigator site TH0660009
-
-
-
-
-
Garran、澳大利亚
- Investigator Site 0610012
-
West Perth、澳大利亚
- Investigator Site 0610003
-
Westmead、澳大利亚
- Investigator site 610005
-
-
-
-
-
Dublin、爱尔兰
- Investigator site 3530003
-
-
-
-
-
Sousse、突尼斯
- Investigator site 2610001
-
Tunis、突尼斯
- Investigator site 2160002
-
-
-
-
-
Irbid、约旦
- Investigator site 9620001
-
-
-
-
-
Bucharest、罗马尼亚
- Investigator Site 0400005
-
Bucharest、罗马尼亚
- Investigator site 400012
-
Craiova、罗马尼亚
- Investigator Site 0400007
-
-
-
-
Arkansas
-
Bentonville、Arkansas、美国、72758
- Investigator Site 0010116
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- Investigator site 0010045
-
-
Indiana
-
Fort Wayne、Indiana、美国、46804
- Investigator Site 0010062
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- Investigator site US0010042
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73142
- Investigator Site 0010095
-
-
-
-
-
Coventry、英国
- Investigator site 440005
-
London、英国
- Investigator site UK044041
-
Penzance、英国、TR18 2PF
- Investigator site UK0440014
-
-
-
-
-
Lisbon、葡萄牙
- Investigator Site 3510007
-
Porto、葡萄牙
- Investigator site 3510004
-
Vila Nova de Gaia、葡萄牙
- Investigator site 3510001
-
-
-
-
-
Buenos Aires、阿根廷
- Investigator Site 0540001
-
Buenos Aires、阿根廷
- Investigator site 540004
-
-
-
-
-
Seoul、韩国
- Investigator site 820004
-
Seoul、韩国
- Investigator site KO0820007
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
- Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period.
- Agree to use contraceptives consistent with local regulations.
- In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period, the participant has completed a 52-week treatment period.
Exclusion criteria:
- Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines).
- Use of any other investigational drug or participation in any other investigational trial.
- Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients.
- Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:efgartigimod PH20 SC
Patients receiving efgartigimod PH20 SC treatment |
Subcutaneous injection with efgartigimod PH20 SC
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of AEs, AESIs, SAEs
大体时间:Up to 216 weeks
|
AE : adverse event ; SAE : Serious adverse event ; AESI : adverse event of special interest. |
Up to 216 weeks
|
|
Vital sign measurement: blood pressure in the overall population
大体时间:Up to 216 weeks
|
Up to 216 weeks
|
|
|
ECG: PR, QT and QRS interval in the overall population
大体时间:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Laboratory safety evaluations: CRP analysis in the overall population
大体时间:Up to 216 weeks
|
Up to 216 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Proportion of participants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment period
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Mean change from baseline in platelet count at each visit
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
For participants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/L
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
The percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
In patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24
大体时间:5 weeks (from week 19 to week 24)
|
5 weeks (from week 19 to week 24)
|
|
|
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24
大体时间:7 weeks (from week 17 to week 24)
|
7 weeks (from week 17 to week 24)
|
|
|
Proportion of participants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baseline
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Rate of receipt of rescue therapy (rescue per participant per month)
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Incidence of the WHO-classified bleeding events
大体时间:Up to 52 weeks
|
WHO : World Health Organization |
Up to 52 weeks
|
|
Serum efgartigimod concentration observed predose (Ctrough)
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Change from baseline in FACIT-fatigue at planned visits
大体时间:Up to 52 weeks
|
The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT- fatigue) scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured by recording item responses on a 4-point Likert scale ranging from 0 "not at all" to 4 "very much." |
Up to 52 weeks
|
|
Change from baseline in FACT-Th6 at planned visits
大体时间:Up to 52 weeks
|
The Functional Assessment of Cancer Therapy questionnaire-Th6 (FACT-Th6) uses the Likert scale, with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. |
Up to 52 weeks
|
|
Change from baseline in SF-36 at planned visits
大体时间:Up to 52 weeks
|
The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. |
Up to 52 weeks
|
|
Change from baseline in ITP-PAQ at planned visits
大体时间:Up to 52 weeks
|
The ITP-Patient Assessment Questionnaire (ITP-PAQ) is a 44-item questionnaire to assess the health-related QoL in adults with ITP. It includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work. |
Up to 52 weeks
|
|
Pharmacodynamics markers: total IgG
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of participants who performed self-administration at home over time
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of caregivers who administered the injection to the patient at home over time
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of self- or caregiver-supported administrations at home
大体时间:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Incidence of antibodies to efgartigimod
大体时间:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Titers of antibodies to efgartigimod
大体时间:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Presence of NAb against efgartigimod
大体时间:Up to 216 weeks
|
NAb : Neutralizing antibodies |
Up to 216 weeks
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.